Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PIK3CA”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Not applicableStudy completedNCT02171286
What this trial is testing

The Oncopanel Pilot (TOP) Study

Who this might be right for
Colorectal Cancer MetastaticAdvanced Non-Small Cell Lung CarcinomaAdvanced Melanoma+2 more
British Columbia Cancer Agency 432
Not applicableEnrolling By InvitationNCT06943313
What this trial is testing

Breast Cancer PET/CT Imaging With 68Ga-pAKTi

Who this might be right for
Breast CancersPIK3CA Mutation-Related TumorsPI3K Pathway Activated Tumors+1 more
Fudan University 20
Testing effectiveness (Phase 2)Looking for participantsNCT07405801
What this trial is testing

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 80
Early research (Phase 1)Looking for participantsNCT07383506
What this trial is testing

Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Who this might be right for
PIK3CA MutationsAdvanced Solid Tumors, AdultEndometrial Cancer+2 more
Cogent Biosciences, Inc. 90
Large-scale testing (Phase 3)Looking for participantsNCT05894239
What this trial is testing

Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 230
Testing effectiveness (Phase 2)Ended earlyNCT02449655
What this trial is testing

Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy

Who this might be right for
Advanced Gastric Adenocarcinoma
Samsung Medical Center 27
Testing effectiveness (Phase 2)UnknownNCT02450656
What this trial is testing

Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer

Who this might be right for
Colorectal NeoplasmsGastrointestinal NeoplasmsPancreatic Neoplasms+1 more
The Netherlands Cancer Institute 320
Testing effectiveness (Phase 2)Ended earlyNCT05082025
What this trial is testing

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Who this might be right for
Endometrial CancerOvarian Cancer
M.D. Anderson Cancer Center 7
Testing effectiveness (Phase 2)Ended earlyNCT03094832
What this trial is testing

Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)

Who this might be right for
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 50
Large-scale testing (Phase 3)Active Not RecruitingNCT05063786
What this trial is testing

Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)

Who this might be right for
Advanced Breast Cancer
Spanish Breast Cancer Research Group 27
Large-scale testing (Phase 3)Looking for participantsNCT06790693
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 450
Testing effectiveness (Phase 2)Active Not RecruitingNCT05625087
What this trial is testing

Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

Who this might be right for
Breast Cancer Stage IV
UNICANCER 162
Large-scale testing (Phase 3)Active Not RecruitingNCT04208178
What this trial is testing

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

Who this might be right for
Advanced HER2+Breast Cancer
Novartis Pharmaceuticals 19
Not applicableStudy completedNCT04480814
What this trial is testing

Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood & Primary Tumor in ER+/HER2- MBC

Who this might be right for
Breast Cancer
Pharmassist Ltd 30
Testing effectiveness (Phase 2)Looking for participantsNCT05306041
What this trial is testing

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
GBG Forschungs GmbH 170
Large-scale testing (Phase 3)Looking for participantsNCT07174336
What this trial is testing

Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Who this might be right for
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company 800
Testing effectiveness (Phase 2)Ended earlyNCT03290092
What this trial is testing

Trial of Taselisib in Overgrowth

Who this might be right for
PIK3CA-Related Overgrowth
Centre Hospitalier Universitaire Dijon 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT05154487
What this trial is testing

Alpelisib and Fulvestrant to Treat Endometrial Cancer

Who this might be right for
Endometroid Endometrial Cancer
GOG Foundation 51
Testing effectiveness (Phase 2)Study completedNCT01277757
What this trial is testing

Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer

Who this might be right for
Recurrent Breast CarcinomaStage IIIB Breast CancerStage IIIC Breast Cancer+1 more
National Cancer Institute (NCI) 30
Next Page